Perimenopause: Protecting Muscle, Bone and Sleep

The printout carries one word: osteopenia. Elsewhere in the documented record, the intervention with the strongest trial evidence looks like this: a supervised gym, twice a week, thirty-minute sessions, five sets of five repetitions above 85 percent of a one-repetition maximum—technique taught before load was added, every participant screened first. And the sleep data comes from 223 women aged 40 to 50, followed every two to six months for two years, whose sleep scores worsened only after their hormones had already shifted, and whose first measurable signal was not a hot flash but feeling too hot to sleep.

That is the shape of the question this article answers: what does the transition do to bone, muscle, and sleep—and what does the strongest trial evidence actually support doing this week?

The defensible answer, in outline: the bone evidence favors supervised high-intensity resistance and impact training under the specific conditions it was tested; the protein and supplement trials in this population found less, and some found nothing; and sleep responds to the structured behavioral treatment with the best evidence in menopausal women. What this article will not do is tell you whether to use menopausal hormone therapy—that is an individualized decision for a clinician who knows your history, and nothing here stands in for it.

What the transition actually does

It is not one hormone doing one thing. The review of global prevalence and physiology in Nature Reviews Endocrinology describes symptoms spanning central nervous system disorders, metabolic, weight, cardiovascular and musculoskeletal changes, urogenital and skin atrophy, and sexual dysfunction, and states the physiology behind them is complex and not reducible to estrogen deprivation alone (Nat Rev Endocrinol, 2018). Ethnic, geographical and individual factors affect how common symptoms are and how severe, which is why a friend's experience forecasts yours poorly.

On timing, the BMJ clinical review reports that vasomotor symptoms are most pronounced during the first four to seven years but can persist for more than a decade, and that genitourinary symptoms tend to be progressive (BMJ, 2023). Alongside hot flashes and night sweats it lists disrupted sleep, mood fluctuation, cognitive change, low sexual desire, bone loss, increased abdominal fat and adverse metabolic changes, arriving in any combination or sequence, with the link to menopause sometimes elusive — and it states that menopausal symptoms remain substantially undertreated. Two things follow. Bone loss and body-composition change are part of the picture, not separate bad luck. And your sleep breaking before your hot flashes started does not mean the two are unrelated.

Sleep: what changes, and when

The review of sleep across the transition in Nature and Science of Sleep reports that 26% of women experience symptoms severe enough to impair daytime functioning and qualify for a diagnosis of insomnia (Nat Sci Sleep, 2018). Longitudinal population studies link sleep difficulty to menopausal stage and to changes in follicle-stimulating hormone and estradiol over and above the effect of age, so this is not simply getting older. Many, though not all, hot flashes are linked with awakenings confirmed on polysomnography, and hot-flash-associated wake time contributes significantly to total wakefulness after sleep onset. The review also flags that some complaints are comorbid with depressive disorders, or attributable to sleep-related breathing or movement disorders, which rise in prevalence especially after menopause.

The most useful study here followed 223 community women aged 40 to 50, mean age 45.6, every two to six months for two years (J Clin Sleep Med, 2023). Sixty-eight entered the transition; 155 remained premenopausal controls and stayed stable throughout. In the transition group, Pittsburgh Sleep Quality Index scores worsened from 5.7 to 6.3 (P = .030) and reports of trouble sleeping because of feeling too hot increased (P = .016) — both lagging the rise in follicle-stimulating hormone by about six months, with no notable change in reported hot flashes or night sweats, and no baseline difference from controls in age, vasomotor symptoms, stress or depression.

Feeling too hot to sleep, as distinct from noticing a hot flash, can therefore be the first measurable signal. Fix the thermal environment and the schedule before concluding the problem is stress. Keep it in proportion, though: that change in sleep score is small. It is evidence about timing, not a claim that everyone's sleep collapses.

Bone: the strongest trial, and the conditions it ran under

The anchor is the LIFTMOR randomized controlled trial (J Bone Miner Res, 2018). Postmenopausal women with low bone mass — a T-score below -1.0, screened for conditions and medications affecting bone and physical function — were randomized to eight months of twice-weekly, 30-minute, supervised high-intensity resistance and impact training at five sets of five repetitions above 85% of one-repetition maximum, or to a home-based low-intensity program. Across 101 women, mean age 65, the training group beat control on lumbar spine bone mineral density (2.9% versus -1.2%, p < 0.001), femoral neck density (0.3% versus -1.9%, p = 0.004), femoral neck cortical thickness (13.6% versus 6.3%, p = 0.014), height (a gain of 0.2 cm versus a loss of 0.2 cm, p = 0.004) and every functional measure tested (p < 0.001). Compliance was 92%, with one adverse event in the whole trial: a minor lower back spasm costing 2 of 70 sessions.

The conditions are the part that gets dropped when this trial is quoted at you. Sessions were supervised, technique was taught before load was added, and participants were screened out for bone-affecting conditions and medications; the authors qualified the safety conclusion as applying under highly supervised conditions in an otherwise healthy sample. The report also carries a published erratum in the same journal (J Bone Miner Res, 2019), worth pulling up if you read the original. Note the population too: postmenopausal women averaging 65 with already-low bone mass, not perimenopausal women in their forties. The loading principle travels. The exact percentages do not.

The follow-up trial, MEDEX-OP, ran the same style of training against a low-intensity, Pilates-based control in 115 postmenopausal women, mean age 63.6, mean femoral neck T-score -1.8, some on stable antiresorptive medication for at least 12 months (J Bone Miner Res, 2021). Over eight months of twice-weekly 40-minute sessions at five sets of five above 80% to 85% of one-repetition maximum, the heavy group improved lumbar spine density more (1.9% versus 0.1%, p < 0.001) and gained stature (0.2 cm versus no change, p = 0.004), and improved more than the control on leg and back strength and five times sit-to-stand (p < 0.05). The most useful hint it offers about progression is a relationship inside the training arms rather than a randomized dose comparison: the women who lifted the most gained the most spine density and the most strength. Compliance was 82.4%, with seven adverse events across all 115 women. An exploratory analysis suggested antiresorptive medication may enhance the exercise effect — a hypothesis, and one the pooled data below did not reproduce.

The pooled picture holds, with caveats. A meta-analysis of exercise intensity covered 53 trials and 63 interventions, only four of them high intensity (Bone, 2021). At the lumbar spine, high intensity produced a larger mean difference (0.031 g/cm2, 95% CI 0.012 to 0.049, p = 0.002) than moderate (0.012) or low (0.010). At the femoral neck, low and moderate were equally effective (both 0.011 g/cm2) and no high-intensity effect was seen, which the authors attribute to probable lack of power rather than a true null. Moderate intensity raised total hip density (0.008 g/cm2, 95% CI 0.004 to 0.012); low intensity did not, and there were too few high-intensity data at the hip to pool. Resistance training, potentially combined with impact training, appeared to be the most effective stimulus at spine and hip.

A newer meta-analysis of resistance training parameters pooled 17 trials in 690 postmenopausal women (J Orthop Surg Res, 2025). Density improved at lumbar spine (SMD 0.88, 95% CI 0.21 to 1.56), femoral neck (SMD 0.89, 95% CI 0.40 to 1.39) and total hip (SMD 0.30, 95% CI 0.10 to 0.50), but not trochanter (SMD 0.23, 95% CI -0.01 to 0.47). The programming advice comes from its subgroups: intensity at or above 70% of one-repetition maximum was significant at total hip and femoral neck; three sessions per week was significant at all four sites; 48 weeks or longer was significant at femoral neck and total hip; 40-minute sessions were significant at the spine. Heterogeneity was very high at spine and femoral neck (I2 91% and 87%), which limits how hard you can lean on those estimates. A separate systematic review of 12 trials found resistance training improved maximal oxygen uptake and upper and lower extremity strength (all p < 0.001), though its pooled effect sizes are so large — standardized mean differences of 2.32, 4.70 and 7.42 — that they almost certainly reflect small, heterogeneous trials rather than what an individual should expect; it calls the influence on bone density more debated and recommends three days per week in 60-minute sessions (Climacteric, 2024).

Four consistent messages. Heavy load moves the spine most: high intensity produced roughly three times the lumbar spine effect of moderate or low intensity, both of which also worked. Three sessions a week has the most consistent support across sites. This is a year-long project. And strength and function improve far more reliably, and faster, than bone density does — which is the outcome that actually keeps you off the floor.

One boundary before the plan. Every bone trial in this article measured bone mineral density and bone geometry. Not one of them measured fractures. The Endocrine Society guideline states as a management principle that multiple pharmacologic therapies are capable of reducing fracture rates in postmenopausal women at risk, with acceptable risk-benefit and safety profiles (J Clin Endocrinol Metab, 2019). Training is not an alternative to that assessment. If your scan or your fracture history puts you in the treatment range, that is a conversation to have with a clinician, and the training goes alongside whatever comes out of it rather than instead of it.

The week

Read the last column first. The heavy protocols above were supervised sessions in which technique was taught before load was added, in participants screened for bone-affecting conditions. That is a condition of the result, not a caveat. Without coaching, run the moderate-intensity version, which still improved femoral neck and total hip density in the pooled data, and add the heavy work when you have supervision.

One note on exercise selection, because this is where articles start inventing. The published reports give intensity, volume, session length and frequency. They do not list the specific lifts or impact drills. The numbers are the prescription; exercise selection is the job of whoever coaches you. What the trials did measure was back and leg strength, which tells you the loading was axial and lower-body dominant.

Progressions, and what to do when it hurts

The progression variable is load, not repetitions, which is what that within-trial relationship between maximum weight lifted and spine density change points to. When five sets of five stop feeling hard, the weight goes up and the reps stay. The timeline is longer than you want. In the resistance training meta-analysis, only programs of 48 weeks or longer reached significance at the femoral neck and total hip, though the two heavy supervised trials moved the femoral neck and the spine in eight months. Judge a moderate-intensity program at the end of a year, and a heavy supervised one at eight months.

Regressions are not failure, and not a null. If heavy work is not available to you, moderate-intensity exercise still improved density at spine, femoral neck and total hip in the pooled data, and low intensity still improved the femoral neck. What low intensity did not do was move the total hip, and neither moved the spine like heavy work did. So the ladder, in order: keep the frequency, keep the session length, drop the impact component first, then range of motion, then load. Frequency is the last thing you give up.

If something hurts, sort it before you load it. Soreness that is symmetrical, arrives a day later and eases with movement is training. Pain that is sharp, one-sided, positional, or runs down a limb with numbness or weakness is not, and whether it is a joint or a nerve problem changes what happens next; our nerve versus joint framework walks through that triage. Two situations need a clinician before the barbell: a previous fracture from a fall from standing height or less, where the Endocrine Society guideline bases decisions on formal fracture-risk assessment with country-specific tools (J Clin Endocrinol Metab, 2019); and current bone medication, where MEDEX-OP deliberately included women on stable antiresorptive therapy and tolerated it well, but with screening and supervision. That is a reason to ask the question, not a permission slip to skip it.

Protein: what the trials in this population found

The training does the work; protein manipulation is a small modifier. One randomized trial, reported in two papers that carry the same trial registration, tested exactly this, so treat the pair as one result rather than two. The first paper randomized 23 postmenopausal women, mean age 63.2, to about 1.2 or about 0.8 g of protein per kg per day, the recommended dietary allowance, while both groups resistance trained three times a week for 10 weeks, progressing from one to six sets of 8 to 12 repetitions (Nutrients, 2017). Intakes separated as intended (1.18 versus 0.87 g per kg per day, p = 0.008). Lean body mass rose in both — 37.1 to 38.4 kg on higher protein (p = 0.004), 37.6 to 38.8 kg on the allowance (p < 0.001) — with no difference between them (p = 0.572). The second reported the fuller sample of 47 women, same registration and same design (Nutrients, 2019): both groups increased leg extension one-repetition maximum and handgrip similarly, both improved on a balance battery and 10 m walk speed with no group difference, and the higher-protein group pulled ahead only on walking endurance, over six minutes and 400 m (interaction p = 0.007 and p = 0.004). The authors note all significant changes had a low effect size.

Supplemented protein behaves the same way. A meta-analysis of whey in women aged 55 and above included 14 studies and pooled 10 (Nutrients, 2022). In the subgroup that also resistance trained, whey improved biceps curl strength (SMD 0.6805, 95% CI 0.176 to 1.185) and lower-limb lean mass (SMD 1.103, 95% CI 0.632 to 1.574). In the subgroup that did not train, it did nothing for strength or lean mass and was associated with a significant fall in dietary protein intake (SMD -0.4225, 95% CI -0.774 to -0.071) — the shake displacing food rather than adding to it. Food protein is modest and safe: a meta-analysis of dairy protein in 14 studies and 1,424 adults aged 61 to 81 found a small gain in appendicular muscle mass of 0.13 kg (95% CI 0.01 to 0.26, p = 0.04), no effect on handgrip (p = 0.13) or leg press (p = 0.89), and no serious adverse events across the nine studies reporting tolerability (Adv Nutr, 2019). A meta-review in adults 65 and over with sarcopenic obesity found exercise with or without added protein improved body fat percentage, gait speed and grip strength, and concluded that because the literature is limited, protein recommendations should align with general sarcopenia recommendations (J Aging Phys Act, 2023).

Timing gets less support than the internet implies. A systematic review of protein around concurrent resistance and endurance exercise found that in all four acute studies, post-exercise protein raised myofibrillar but not mitochondrial protein synthesis rates — in 84 trained young males, which is not you (Sports Med, 2022). Over longer training, five of nine studies found supplementation added to muscle mass gains and five of nine to strength or power, and all six that measured aerobic capacity found no effect. So: the range tested in postmenopausal women who lift is roughly 0.8 to 1.2 g per kg per day, the higher end did not beat the allowance for lean mass or strength in either report, and no trial here tested a per-meal gram target, so this article will not invent one. Our protein and macro calculator will show where your intake sits against the range that was actually studied.

The supplement aisle, graded

The tiers run strong, moderate, emerging, preliminary and tested-and-did-not-work, and the criteria are in how we grade evidence. Applied here, the aisle is thinner than the shelf space suggests.

Creatine earns its own paragraph as the only supplement here with a two-year randomized trial in roughly the right population. Two hundred and thirty-seven postmenopausal women, mean age 59, took creatine monohydrate at 0.14 g per kg of body weight per day or placebo while resistance training three days a week and walking six days a week for two years (Med Sci Sports Exerc, 2023). The primary outcome was femoral neck bone mineral density, and creatine did nothing to it, nor to total hip or lumbar spine. It did maintain section modulus at the narrow part of the femoral neck, a measure predictive of bone bending strength (p = 0.0011), and buckling ratio at the same site (p = 0.011), and it cut walking time over 80 m from 48.6 to 47.1 seconds against essentially no change on placebo (p = 0.0008). It did nothing for strength: hack squat one-repetition maximum went from 57.6 to 84.4 kg on creatine and 56.6 to 82.7 kg on placebo, with the same pattern for bench press. A subanalysis restricted to valid completers found creatine increased lean tissue mass relative to placebo (p = 0.046).

The important number there is not the creatine effect. Both arms raised their hack squat by a similar, large margin over two years — that was the training. Creatine, at the dose used in that trial, changed some bone geometry and a walking time and did not change the outcome it was designed to change. A fair reason to consider it; a bad reason to prioritize it over the training. We cover the wider muscle and brain evidence in our creatine and healthy aging review, and the creatine monohydrate page lists the plain single-ingredient form that was studied.

Calcium and vitamin D need care, because the largest analysis is easy to misread. Across 69 randomized trials in 153,902 adults not receiving drug treatment for osteoporosis, there was little to no effect on the risk of any fracture from calcium (risk ratio 0.91, 95% CI 0.81 to 1.01, moderate certainty), vitamin D (1.00, 95% CI 0.95 to 1.06, high certainty) or combined supplementation (0.91, 95% CI 0.84 to 0.99, high certainty), with similar results for hip, non-vertebral and vertebral fracture and for falls (BMJ, 2026). Most participants were community dwelling and not at high risk, and evidence in high-risk or residential-care populations remains limited. What that does not say is that these nutrients are irrelevant to someone already being treated for osteoporosis: the Endocrine Society guideline, which addresses women who carry that diagnosis, states as a management principle that nutritional and lifestyle interventions and fall prevention should accompany all pharmacologic regimens. Two different questions, two different answers. For the general case, food first is the defensible default — our grocery swaps list the food sources.

Menopausal hormone therapy: what the reviews report

This section is deliberately flat. It reports what the review papers say and stops. It does not recommend for or against, and it cannot substitute for the individualized decision you make with a clinician who knows your history and your preferences — which is how both reviews frame it.

The Human Reproduction Update appraisal reports that hormone therapy is an effective treatment for bothersome vasomotor symptoms and genitourinary syndrome and for prevention of osteoporotic fractures (Hum Reprod Update, 2021). It states women should be made aware of a small increased risk of stroke that tends to persist over the years, and of breast cancer risk with long-term estrogen-progestin use. Those two are the risks that review names, set against the benefits it lists below; it also notes that the route of administration matters for clotting risk and that contraindications exist, so the same ledger does not come out the same way for two different readers. It reports offsetting effects including cardiovascular risk reduction, increased bone mineral density, reduced fracture risk, decreased colorectal cancer risk with estrogen-progestin therapy, and an overall but nonsignificant reduction in mortality. On administration it states a preference where possible for transdermal routes, which have least impact on coagulation, and for natural progesterone in combined treatment, starting low and increasing gradually, with regular reassessment described as mandatory. It also notes that among women with premature menopause, meaning ovarian failure well before the usual age, those who begin hormone therapy before 50 appear to have the largest longevity advantage, which is a point about that specific group rather than about starting earlier in general. The BMJ review states that estrogen-based hormonal therapies are the most effective treatments for many symptoms and, absent contraindications, have a generally favorable benefit-to-risk ratio for women below age 60 and within 10 years of the onset of menopause, and that non-hormonal options are also available. In the MsFLASH network, which tested nine interventions in over 1,300 women, low-dose estradiol reduced hot flashes by approximately 50% against a 30% decrease on placebo, and a selective serotonin reuptake inhibitor and a serotonin-norepinephrine reuptake inhibitor tested in the same network produced a similar magnitude of reduction (Menopause, 2020).

That is the whole of what this article will say. Take those findings to the appointment; do not take them as the decision.

Sleep: a protocol shaped like the treatment that works

The best-supported non-drug treatment here is cognitive behavioral therapy for insomnia. A meta-analysis of 11 randomized trials in 973 menopausal women found it improved sleep quality (SMD -1.01, 95% CI -1.27 to -0.75) and reduced insomnia severity (mean difference -4.49 points, 95% CI -6.12 to -2.87), across programs of 4 to 12 sessions with follow-up to 52 weeks, and effective regardless of face-to-face or remote delivery, follow-up duration, or baseline severity (Womens Health Nurs, 2025). In MsFLASH it reduced self-reported insomnia symptoms and improved overall sleep quality against a menopause education control — an active comparator, and a harder test than a waitlist. A small trial in 44 women, using one group session of sleep hygiene education plus four individual counseling sessions, found significant group effects on insomnia and sleep quality (West J Nurs Res, 2020); one small trial, weighted accordingly.

What follows is the shape of that treatment, with the caveat first: the trials tested a structured program delivered by a trained person, not a do-it-yourself subset of its components. Running the components alone is a reasonable first move, not the same intervention.

1. Fix the rise time first. One wake time, every day including weekends, regardless of how the night went. Everything else is built on that anchor.
2. Compress the sleep window to the sleep you are actually getting, then extend as your sleep becomes more efficient. This does most of the work, feels worst in the first week, and is the easiest component to do badly alone — the strongest argument for getting the real program.
3. Stimulus control. The bed is for sleep and sex. If you are lying there long enough to get frustrated, get up, go somewhere dim and dull, and return when you are sleepy rather than when you think you should be.
4. Treat temperature as a primary variable, not a comfort preference. Trouble sleeping because of feeling too hot was the symptom that tracked the rise in follicle-stimulating hormone, and it did so without any increase in reported hot flashes. Cool room, layers you can shed without waking anyone, separate covers if night sweats are waking a partner.
5. Do not schedule-manage a different disorder. Snoring, waking with a gasp, witnessed pauses in breathing, or an irresistible urge to move the legs at night are reasons for assessment, not reasons to tighten your sleep window.

What to skip

Exercise or yoga bought specifically as a hot flash treatment. The Cochrane review included five trials in 733 women and found no difference between exercise and no active treatment in the frequency or intensity of vasomotor symptoms (SMD -0.10, 95% CI -0.33 to 0.13), and none between exercise and yoga (SMD -0.03, 95% CI -0.45 to 0.38), rating the evidence low quality throughout; in one small comparison the hormone therapy group reported significantly fewer flushes in 24 hours than the exercise group, but that comparison had 14 participants (Cochrane Database Syst Rev, 2014). Cochrane's own verdict was that the evidence is insufficient to show whether exercise works for vasomotor symptoms, not that exercise was shown to fail. MsFLASH reached the same negative conclusion for yoga and exercise against usual activity. In fairness to the other side, a 15-week open randomized trial of resistance training three times a week in 65 postmenopausal women with daily vasomotor symptoms improved the vasomotor (p = 0.002), sleep problems (p = 0.003) and menstrual symptoms (p = 0.01) domains of a menopause-specific quality of life questionnaire, with no differences on a general health survey (Climacteric, 2022) — unblinded, against an untreated control, so expectancy is a live explanation. Train for bone, strength and function, and treat symptom relief as a bonus.

Omega-3 for hot flashes. No benefit against placebo in MsFLASH. Whatever the case for omega-3 rests on, and we review that case in our omega-3 evidence article, vasomotor symptoms are not it.

Calcium and vitamin D as your fracture strategy, if you are not being treated for osteoporosis. Being replete is a reasonable nutritional goal; supplementing to prevent fractures is not supported by that analysis.

Protein powder without the training. The non-training subgroup got nothing for strength or lean mass and had lower dietary protein intake. The powder supplements a stimulus; it does not substitute for one.

Low-intensity-only exercise, if the spine is your concern. High intensity beat both moderate and low at the lumbar spine, and low intensity did not move the total hip at all.

Judging a short program short. In the duration subgroups of the resistance training meta-analysis, only programs of 48 weeks or longer reached significance at the femoral neck and total hip, though the two supervised heavy trials moved the femoral neck and the spine in eight months. Quitting after a few months because the scan has not moved means quitting before the intervention has run.

Proprietary blends and the panels sold with them. A blend that does not disclose per-ingredient doses cannot be lined up against any trial in this article, which means it cannot be evaluated at all. And a hormone panel whose output is a product recommendation is a sales instrument, not a diagnostic one. Testing should change a decision a clinician is making with you; if the only decision it changes is what you buy from the company that ran it, that is the tell.

Red flags: stop and get assessed

Bleeding after menopause. Any vaginal bleeding a year or more after your last period needs to be investigated, not watched. It is the cardinal symptom of endometrial cancer, most cases turn out to be something else, and the point of going quickly is to find the ones that are not. Ask for an urgent appointment, days rather than months, and say the words "postmenopausal bleeding" when you book it. New or unscheduled bleeding while on hormone therapy needs the same conversation. None of this is a supplement question. In perimenopause, bleeding that is newly very heavy, much longer than your usual, or between cycles also warrants assessment rather than watchful waiting.

A fracture from a fall from standing height or less. That is a fragility fracture and it changes your category. The Endocrine Society guideline bases treatment decisions on formal fracture-risk assessment with country-specific tools, and states fall prevention and nutritional and lifestyle measures should accompany any pharmacologic regimen. This is where a heavy program gets built with a clinician rather than around one.

Measured height loss. Both heavy-training trials measured stature. In LIFTMOR the training group gained 0.2 cm while controls lost 0.2 cm; in MEDEX-OP the training group gained 0.2 cm while controls held steady. Height loss can reflect vertebral fracture. Measure it consistently, and take a real loss to a clinician for imaging rather than adding load on your own.

Depressive symptoms. The sleep literature in this population is explicit that some sleep complaints are comorbid with depressive disorders, and that severe insomnia left untreated in midlife may have consequences beyond immediate quality of life. Persistent low mood, loss of interest in things you used to want, or hopelessness is a same-week clinician conversation, not a sleep-schedule problem — and any thought of self-harm means today, not next week.

Pain that does not behave like training. New neurological symptoms in a limb, pain that wakes you rather than being provoked by movement, unexplained weight loss with back pain, or chest pain and breathlessness on exertion all mean stop and get assessed. The heavy trials screened participants before loading them; that is a standard worth borrowing.

How to know it is working

Bone density moves slowly and is measured rarely. Function moves quickly and you can measure it at home. Track the fast markers and let the slow one confirm.

Norm-referenced tests beat a subjective sense of getting stronger. Our Movement Lab runs grip and sit-to-stand style tests against population norms on your own device, and the Biomarker Tracker holds the cited lab markers in one place. Take both to the appointment where your bone density is discussed. A scan read next to a rising sit-to-stand score and a stable height is a different conversation from a scan read alone.

Bottom line

Heavy, supervised, technique-first resistance training is the intervention with the best evidence here for bone density, strength and function in the postmenopausal women these trials studied, and no product replaces it. What it does not replace is a treatment conversation, because none of these trials measured fractures. Protein and supplements are modifiers around it, sized honestly. Sleep responds to a structured behavioral program rather than a schedule tweak, and temperature deserves more attention than it gets. Everything above about hormone therapy is reporting, not advice. Educational, not medical advice.